Gene therapy has long promised to cure genetic disorders by fixing faulty DNA, yet delivery challenges have slowed its progress. Fuse Vectors, a Copenhagen-based biotech startup, is tackling these hurdles with an innovative cell-free viral vector production platform, designed to improve scalability and safety in gene therapy (Chemical & Engineering News, 2025).
Traditional gene therapy relies on viral vectors produced inside living cells—a costly, inefficient process. Fuse Vectors has developed a cell-free platform for generating adeno-associated virus (AAV) vectors, improving efficiency while reducing contamination risks. This breakthrough could make gene therapies more accessible for rare genetic diseases (BioPharma Trend, 2025).
Fuse Vectors recently secured $5.2 million in pre-seed funding, led by HCVC, underscoring investor confidence in its disruptive approach (BioPharma Trend, 2025). If successful, their scalable vector production could accelerate clinical trials and bring gene therapies to market faster.
By optimizing vector manufacturing, Fuse Vectors aims to reduce gene therapy costs and increase accessibility, paving the way for treatments across multiple genetic disorders. As gene therapy advances, breakthroughs like this will be critical to overcoming manufacturing bottlenecks in the field.
Sources: Chemical & Engineering News, BioPharma Trend
Helping biotech startups and professionals scale smarter with the right match.